Retatrutide: Why Muscle Loss Data Doesn’t Match Real Life

For the written breakdown, early access to information like this, and extra nuances, see the associated StayCurious Metabolism Newsletter: https://staycuriousmetabolism.substack.com/p/change-your-mind-on-weight-loss-drugs?r=444440ekz2 Retatrutide (a GLP-3 drug) is often described as “muscle-sparing,” yet clinical trials in obesity show ~38% of weight loss may come from lean mass. So why do some real-world reports suggest otherwise? One hypothesis involves its glucagon component increasing FGF21, a hormone linked to higher energy expenditure and fat burning that may also be muscle-sparing. However, obesity is an FGF21-resistant state, meaning responses could differ based on metabolic health. #GLP1 #Retatrutide #MetabolicHealth #FatLossScience #Hormones #MuscleMass #StayCurious